Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-asparaginase intervals in acute lymphoblastic leukemia
NCT00819351Phase 3
Key facts
- Status
- Completed
- Start
- Jan 2009
- Primary completion
- Mar 2016
- Countries
- 5
- Sponsor
- Rigshospitalet
- Modality
- Therapeutic Enzymes
- Drugs
- pegaspargase
- Conditions
- acute lymphoblastic leukemia (ALL)
01
Overview
Phase 3, randomised, open-label trial of pegaspargase in acute lymphoblastic leukemia (ALL), sponsored by Rigshospitalet. Started Jan 2009; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Children and young adults with newly diagnosed acute lymphoblastic leukemia, excluding those with bilineage ALL or significant pre-treatment.
04
Registry description
The purpose of this study is to investigate if intramuscular PEG-asparaginase administered either at six or two week intervals from day 92 until 8 months from diagnosis for patients with non-HR ALL will result in equal probability of Event Free Survival
Beyond the preview
Go deeper on NCT00819351.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00819351.